Obesity is a global public health issue. Although the etiology of this global epidemic is multifactorial, most sufferers would be delighted to find a relatively effortless way to lose weight. Herbal “weight loss pills” can fit the bill. The authors systematically review the scientific evidence concerning various weight loss agents that are available over the counter or in food stores. The review provides a starting point to make informed choices among nutraceutical agents promoted for weight loss, as well as advice for incorporating healthy alternatives in the diet.
FlegalKMCarrollMDOgdenCLCurtinLR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-241.
2.
NguyenDMEl-SeragHB. The epidemiology of obesity. Gastroenterol Clin North Am. 2010;39:1-7.
3.
GrimmERSteinleNI. Genetics of eating behavior: established and emerging concepts. Nutr Rev. 2011;69:52-60.
4.
LakeATownshendT. Obesogenic environments: exploring the built and food environments. J R Soc Promot Health. 2006;126:262-267.
5.
BoothKMPinkstonMMPostonWS. Obesity and the built environment. J Am Diet Assoc. 2005;105:S110-S117.
6.
DavisMAWestANWeeksWBSirovichBE. Health behaviors and utilization among users of complementary and alternative medicine for treatment versus health promotion. Health Serv Res. 2011May10 [Epub ahead of print]. doi: 10.1111/j.1475-6773.2011.01270.x10.1111/j.1475-6773.2011.01270.x.
7.
NahinRLBarnesPMStussmanBJBloomB. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Rep. 2009;18:1-14.
8.
EisenbergDMKesslerRCFosterCNorlockFECalkinsDRDelbancoTL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246-252.
9.
SaperRBEisenbergDMPhillipsRS. Common dietary supplements for weight loss. Am Fam Physician. 2004;70:1731-1738.
10.
BlanckHMSerdulaMKGillespieC. Use of nonprescription dietary supplements for weight loss is common among Americans. J Am Diet Assoc. 2007;107:441-447.
11.
BertischSMWeeCCMcCarthyEP. Use of complementary and alternative therapies by overweight and obese adults. Obesity. 2008;16:1610-1615.
12.
PillitteriJLShiffmanSRohayJMHarkinsAMBurtonSLWaddenTA. Use of dietary supplements for weight loss in the United States: results of a national survey. Obesity. 2008;16:790-796.
13.
SlavinJL. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc. 2008;108(10):1716-1731.
14.
O’NeilCENicklasTAZanovecMChoS. Whole-grain consumption is associated with diet quality and nutrient intake in adults: the National Health and Nutrition Examination Survey, 1999-2004. J Am Diet Assoc. 2010;110:1461-1468.
15.
BlanckHMGillespieCKimmonsJESeymourJDSerdulaMK. Trends in fruit vegetable consumption among U.S. men and women, 1994-2005. Prev Chronic Dis. 2008;5:A35.
16.
NicklasTAFarrisRPMyersLBerensonGS. Dietary fiber intake of children and young adults: the Bogalusa Heart Study. J Am Diet Assoc. 1995;95:209-214.
17.
Ello-MartinJARoeLSLedikweJHBeachAMRollsBJ. Dietary energy density in the treatment of obesity: a year-long trial comparing 2 weight-loss diets. Am J Clin Nutr. 2007;85:1465-1477.
18.
LedikweJHBlanckHMKettel KhanL. Dietary energy density is associated with energy intake and weight status in US adults. Am J Clin Nutr. 2006;83:1362-1368.
19.
KantAKGraubardBI. Energy density of diets reported by American adults: association with food group intake, nutrient intake, and body weight. Int J Obes (Lond). 2005;29(8):950-956.
20.
LedikweJHBlanckHMKhanLK. Low-energy-density diets are associated with high diet quality in adults in the United States. J Am Diet Assoc. 2006;106:1172-1180.
21.
LiuSWillettWCMansonJEHuFBRosnerBColditzG. Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women. Am J Clin Nutr. 2003;78:920-927.
22.
Bes-RastrolloMMartínez-GonzálezMASánchez-VillegasAde la Fuente ArrillagaCMartínezJA. Association of fiber intake and fruit/vegetable consumption with weight gain in a Mediterranean population. Nutrition. 2006;22(5):504-511.
23.
VioqueJWeinbrennerTCastellóAAsensioLGarcia de la HeraM. Intake of fruits and vegetables in relation to 10-year weight gain among Spanish adults. Obesity. 2008;16:664-670.
24.
DuHvan der ADLBoshuizenHC. Dietary fiber and subsequent changes in body weight and waist circumference in European men and women. Am J Clin Nutr. 2010;91:329-336.
25.
JonesJRLinebackDMLevineMJ. Dietary reference intakes: implications for fiber labeling and consumption: a summary of the International Life Sciences Institute North America Fiber Workshop, June 1-2, 2004, Washington, DC. Nutr Rev. 2006;64:31-38.
SamraRAAndersonGH. Insoluble cereal fiber reduces appetite and short-term food intake and glycemic response to food consumed 75 min later by healthy men. Am J Clin Nutr. 2007;86:972-979.
28.
LeeYPMoriTASipsasS. Lupin-enriched bread increases satiety and reduces energy intake acutely. Am J Clin Nutr. 2006;84:975-980.
29.
HuntRFedorakRFrohlichJMcLennanCPavilanisA. Therapeutic role of dietary fibre. Can Fam Physician. 1993;39:897-900, 903-910.
30.
LeungAYFosterS. Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics. 2nd ed.New York: John Wiley; 1996.
31.
CiceroAFDerosaGMancaMBoveMBorghiCGaddiAV. Different effect of psyllium and guar dietary supplementation on blood pressure control in hypertensive overweight patients: a six-month, randomized clinical trial. Clin Exp Hypertens. 2007;29:383-394.
32.
SartoreGReitanoRBarisonA. The effects of psyllium on lipoproteins in type II diabetic patients. Eur J Clin Nutr. 2009;63:1269-1271.
33.
PalSKhossousiABinnsCDhaliwalSEllisV. The effect of a fibre supplement compared to a healthy diet on body composition, lipids, glucose, insulin and other metabolic syndrome risk factors in overweight and obese individuals. Br J Nutr. 2011;105:90-100.
34.
Salas-SalvadóJFarrésXLuqueX. Fiber in Obesity-Study Group: effect of two doses of a mixture of soluble fibres on body weight and metabolic variables in overweight or obese patients: a randomised trial. Br J Nutr. 2008;99:1380-1387.
35.
Rodríguez-MoránMGuerrero-RomeroFLazcano-BurciagaG. Lipid- and glucose-lowering efficacy of Plantago psyllium in type II diabetes. J Diabetes Complications. 1998;12:273-278.
36.
GiacosaARondanelliM. The right fiber for the right disease: an update on the psyllium seed husk and the metabolic syndrome. J Clin Gastroenterol. 2010;44(suppl 1):S58-S60.
37.
ZiaiSALarijaniBAkhoondzadehS. Psyllium decreased serum glucose and glycosylated hemoglobin significantly in diabetic outpatients. J Ethnopharmacol. 2005;102:202-207.
38.
BrownLRosnerBWillettWWSacksFM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69:30-42.
39.
KeithleyJSwansonB. Glucomannan and obesity: a critical review. Altern Ther Health Med. 2005;11:30-34.
40.
WalshDEYaghoubianVBehforoozA. Effect of glucomannan on obese patients: a clinical study. Int J Obes. 1984;8:289-293.
41.
WoodRJFernandezMLSharmanMJ. Effects of a carbohydrate-restricted diet with and without supplemental soluble fiber on plasma low-density lipoprotein cholesterol and other clinical markers of cardiovascular risk. Metabolism. 2007;56:58-67.
42.
VuksanVSievenpiperJLOwenR. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care. 2000;23:9-14.
43.
VuksanVJenkinsDJSpadaforaP. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes: a randomized controlled metabolic trial. Diabetes Care. 1999;22:913-919.
44.
LenzTLHamiltonWR. Supplemental products used for weight loss. J Am Pharm Assoc. 2004;44:59-67.
45.
GallaherCMMunionJHesslinkRJrWiseJGallaherDD. Cholesterol reduction by glucomannan and chitosan is mediated by changes in cholesterol absorption and bile acid and fat excretion in rats. J Nutr. 2000;130:2753-2759.
46.
GallaherDDGallaherCMMahrtGJCarrTPHollingsheadCHHesslinkRJrWiseJ. A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. J Am Coll Nutr. 2002;21:428-433.
47.
WydroPKrajewskaBHac-WydroK. Chitosan as a lipid binder: a langmuir monolayer study of chitosan-lipid interactions. Biomacromolecules. 2007;8:2611-2617.
48.
MhurchuCNDunshea-MooijCBennettDRodgersA. Effect of chitosan on weight loss in overweight and obese individuals: a systematic review of randomized controlled trials. Obes Rev. 2005;6:35-42.
49.
MhurchuCNPoppittSDMcGillAT. The effect of the dietary supplement, chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord. 2004;28:1149-1156.
50.
Hernández-GonzálezSOGonzález-OrtizMMartínez-AbundisERobles-CervantesJA. Chitosan improves insulin sensitivity as determined by the euglycemic-hyperinsulinemic clamp technique in obese subjects. Nutr Res. 2010;30:392-395.
51.
PittlerMHAbbotNCHarknessEFErnstE. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr. 1999;53(5):379-381.
52.
HoSCTaiESEngPHTanCEFokAC. In the absence of dietary surveillance, chitosan does not reduce plasma lipids or obesity in hypercholesterolaemic obese Asian subjects. Singapore Med J. 2001;42(1):6-10.
53.
JullABNi MhurchuCBennettDADunshea-MooijCARodgersA. Chitosan for overweight or obesity. Cochrane Database Syst Rev. 2008;(3):CD003892.
54.
WuolijokiEHirveläTYlitaloP. Decrease in serum LDL cholesterol with microcrystalline chitosan. Methods Find Exp Clin Pharmacol. 1999;21:357-361.
55.
SchillerRNBarragerESchaussAGNicholsEJ. A randomized, double-blind, placebo-controlled study examining the effects of a rapidly soluble chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals. J Am Nutraceut Assn. 2001;4:42-49.
56.
KaatsGRMichalekJEPreussHG. Evaluating efficacy of a chitosan product using a double-blinded, placebo-controlled protocol. J Am Coll Nutr. 2006;25:389-394.
57.
KovacsEMWesterterp-PlantengaMSSarisWHGoossensIGeurtenPBrounsF. The effect of addition of modified guar gum to a low-energy semisolid meal on appetite and body weight loss. Int J Obes Relat Metab Disord. 2001;25:307-315.
58.
EvansEMillerDS. Bulking agents in the treatment of obesity. Nutr Metab. 1975;18:199-203.
59.
KovacsEMWesterterp-PlantengaMSSarisWH. The effect of guar gum addition to a semisolid meal on appetite related to blood glucose, in dieting men. Eur J Clin Nutr. 2002;56:771-778.
60.
LylyMLiukkonenKHSalmenkallio-MarttilaMKarhunenLPoutanenKLähteenmäkiL. Fibre in beverages can enhance perceived satiety. Eur J Nutr. 2009;48:251-258.
61.
PittlerMHErnstE. Guar gum for body weight reduction: meta-analysis of randomized trials. Am J Med. 2001;110:724-730.
62.
McCartyMF. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. Med Hypotheses. 1994;42:215-225.
63.
HeymsfieldSBAllisonDBVasselliJRPietrobelliAGreenfieldDNunezC. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998;280:1596-1600.
64.
VasquesCARossettoSHalmenschlagerG. Evaluation of the pharmacotherapeutic efficacy of Garcinia cambogia plus Amorphophallus konjac for the treatment of obesity. Phytother Res. 2008;22:1135-1140.
65.
KovacsEMWesterterp-PlantengaMSde VriesMBrounsFSarisWH. Effects of 2-week ingestion of (–)-hydroxycitrate and (–)-hydroxycitrate combined with medium-chain triglycerides on satiety and food intake. Physiol Behav. 2001;74:543-549.
66.
PreussHGGarisRIBrambleJD. Efficacy of a novel calcium/potassium salt of (–)-hydroxycitric acid in weight control. Int J Clin Pharmacol Res. 2005;25:133-144.
67.
KriketosADThompsonHRGreeneHHillJO. (–)-Hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorptive state. Int J Obes Relat Metab Disord. 1999;23:867-873.
68.
LimKRyuSNhoHS. (–)-Hydroxycitric acid ingestion increases fat utilization during exercise in untrained women. J Nutr Sci Vitaminol (Tokyo). 2003;49:163-167.
69.
PreussHGRaoCVGarisR. An overview of the safety and efficacy of a novel, natural (–)-hydroxycitric acid extract (HCA-SX) for weight management. J Med. 2004;35:33-48.
70.
BhattacharyaABanuJRahmanMCauseyJFernandesG. Biological effects of conjugated linoleic acids in health and disease. J Nutr Biochem. 2006;17:789-810.
71.
PlourdeMJewSCunnaneSCJonesPJ. Conjugated linoleic acids: why the discrepancy between animal and human studies?Nutr Rev. 2008;66:415-421.
72.
KanayaNChenS. Conjugated linoleic acid reduces body weight gain in ovariectomized female C57BL/6J mice. Nutr Res. 2010;30:714-721.
73.
JosephSVLiuXWakefieldA. Trans-8, cis-10+ cis-9, trans-11-conjugated linoleic acid mixture alters body composition in Syrian golden hamsters fed a hypercholesterolaemic diet. Br J Nutr. 2010;104:1443-1449.
74.
WendelAAPurushothamALiuLFBeluryMA. Conjugated linoleic acid induces uncoupling protein 1 in white adipose tissue of ob/ob mice. Lipids. 2009;44:975-982.
75.
ParraPSerraFPalouA. Moderate doses of conjugated linoleic acid isomers mix contribute to lowering body fat content maintaining insulin sensitivity and a noninflammatory pattern in adipose tissue in mice. J Nutr Biochem. 2010;21:107-115.
76.
HaladeGVRahmanMMWilliamsPJFernandesG. Combination of conjugated linoleic acid with fish oil prevents age-associated bone marrow adiposity in C57Bl/6J mice. J Nutr Biochem. 2011;22:459-469.
77.
LarsenTMToubroSGudmundsenOAstrupA. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain. Am J Clin Nutr. 2006;83:606-612.
78.
Malpuech-BrugèreCVerboeket-van de VenneWPMensinkRP. Effects of two conjugated linoleic acid isomers on body fat mass in overweight humans. Obes Res. 2004;12:591-598.
79.
VenkatramananSJosephSVChouinardPYJacquesHFarnworthERJonesPJ. Milk enriched with conjugated linoleic acid fails to alter blood lipids or body composition in moderately overweight, borderline hyperlipidemic individuals. J Am Coll Nutr. 2010;29:152-159.
80.
WhighamLDWatrasACSchoellerDA. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J Clin Nutr. 2007;85:1203-1211.
81.
GaullierJMHalseJHøyeK. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin Nutr. 2004;79:1118-1125.
82.
WatrasACBuchholzACCloseRNZhangZSchoellerDA. The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain. Int J Obes (Lond). 2007;31:481-487.
83.
KhanNMukhtarH. Tea polyphenols for health promotion. Life Sci. 2007;81:519-533.
84.
Perva-UzunalićAŠkergetMKnezŽWeinreichBOttoFGrünerS. Extraction of active ingredients from green tea (Camellia sinensis): extraction efficiency of major catechins and caffeine. Food Chem. 2006;96:597-605.
85.
CrossSEJinYSLuQYRaoJGimzewskiJK. Green tea extract selectively targets nanomechanics of live metastatic cancer cells. Nanotechnology. 2011;22:215101.
86.
RoyAMBaligaMSKatiyarSK. Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol Cancer Ther. 2005;4:81-90.
87.
SadavaDWhitlockEKaneSE. The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun. 2007;360:233-237.
88.
TranPLKimSAChoiHSYoonJHAhnSG. Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo. BMC Cancer. 2010;10:276.
89.
IkedaI. Multifunctional effects of green tea catechins on prevention of the metabolic syndrome. Asia Pac J Clin Nutr. 2008;17:273-274.
90.
WangHWenYDuY. Effects of catechin enriched green tea on body composition. Obesity. 2010;18:773-779.
91.
NagaoTMeguroSHaseT. A catechin-rich beverage improves obesity and blood glucose control in patients with type 2 diabetes. Obesity. 2009;17:310-317.
92.
NagaoTHaseTTokimitsuI. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity. 2007;15:1473-1483.
93.
MakiKCReevesMSFarmerM. Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults. J Nutr. 2009;139:264-270.
94.
NagaoTKomineYSogaS. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Am J Clin Nutr. 2005;81:122-129.
95.
RainsTMAgarwalSMakiKC. Antiobesity effects of green tea catechins: a mechanistic review. J Nutr Biochem. 2011;22:1-7.
96.
HurselRViechtbauerWWesterterp-PlantengaMS. The effects of green tea on weight loss and weight maintenance: a meta-analysis. Int J Obes. 2009;33:956-961.
97.
DiepvensKKovacsEMVogelsNWesterterp-PlantengaMS. Metabolic effects of green tea and of phases of weight loss. Physiol Behav. 2006;87:185-191.
98.
DiepvensKKovacsEMNijsIMVogelsNWesterterp-PlantengaMS. Effect of green tea on resting energy expenditure and substrateoxidation during weight loss in overweight females. Br J Nutr. 2005;94:1026-1034.
99.
Westerterp-PlantengaMSLejeuneMPKovacsEM. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Obes Res. 2005;13:1195-1204.
100.
AstrupAToubroCCannonSHeinPBreumLMadsenJ. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. Am J Clin Nutr. 1990;51:759-767.
101.
HeRRChenLLinBHMatsuiYYaoXSKuriharaH. Beneficial effects of oolong tea consumption on diet-induced overweight and obese subjects. Chin J Integr Med. 2009;15:34-41.
102.
HanLKTakakuTLiJKimuraYOkudaH. Anti-obesity action of oolong tea. Int J Obes Relat Metab Disord. 1999;23(1):98-105.
103.
HeckmanMAWeilJGonzalez de MejiaE. Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters. J Food Sci. 2010;75:R77-R87.
104.
PhungOJBakerWLMatthewsLJLanosaMThorneAColemanCI. Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis. Am J Clin Nutr. 2010;91:73-81.
105.
AstrupABreumLToubroSHeinPQuaadeF. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial. Int J Obes Relat Metab Disord. 1992;16:269-277.
106.
Lopez-GarciaEvan DamRMRajpathakSWillettWCMansonJEHuFB. Changes in caffeine intake and long-term weight change in men and women. Am J Clin Nutr. 2006;83:674-680.
107.
DullooAGeisslerCHortonTMillerD. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. Am J Clin Nutr. 1989;49:44-50.
108.
HorstKWillsonRJSmithRG. The effect of coffee and decaffeinated coffee on oxygen consumption, pulse rate and blood pressure. J Pharmacol Exp Ther. 1936;58:294-304.
109.
AchesonKJZahorska-MarkiewiczBAnantharamanKJequierE. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Am J Clin Nutr. 1980;33:989-997.
110.
BenowitzNLJacobPIIIMayanHDenaroC. Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther. 1995;58:684-691.
111.
KraemerWJVolekJSDunn-LewisC. L-carnitine supplementation: influence upon physiological function. Curr Sports Med Rep. 2008;7:218-223.
112.
HathcockJNShaoA. Risk assessment for carnitine. Regul Toxicol Pharmacol. 2006;46:23-28.
113.
KarlicHLohningerA. Supplementation of L-carnitine in athletes: does it make sense?Nutrition. 2004;20:709-715.
114.
MüllerDMSeimHKiessWLösterHRichterT. Effects of oral L-carnitine supplementation on in vivo long-chain fatty acid oxidation in healthy adults. Metabolism. 2002;51:1389-1391.
115.
RonnettGVKimEKLandreeLETuY. Fatty acid metabolism as a target for obesity treatment. Physiol Behav. 2005;85:25-35.
116.
JiHFriedmanMI. Reduced capacity for fatty acid oxidation in rats with inherited susceptibility to diet-induced obesity. Metabolism. 2007;56:1124-1130.
117.
FabrisRMingroneGMilanG. Further lowering of muscle lipid oxidative capacity in obese subjects after biliopancreatic diversion. J Clin Endocrinol Metab. 2004;89:1753-1759.
118.
KelleyDEGoodpasterBWingRRSimoneauJA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol. 1999;277:E1130-E1141.
119.
MeltonSAKeenanMJStanciuCE. L-carnitine supplementation does not promote weight loss in ovariectomized rats despite endurance exercise. Int J Vitam Nutr Res. 2005;75(2): 156-160.
120.
Saldanha AokiMRodriguez Amaral AlmeidaALNavarroFBicudo Pereira Costa-RosaLFPereira BacurauRF. Carnitine supplementation fails to maximize fat mass loss induced by endurance training in rats. Ann Nutr Metab. 2004;48:90-94.
121.
BrandschCEderK. Effect of L-carnitine on weight loss and body composition of rats fed a hypocaloric diet. Ann Nutr Metab. 2002;46:205-210.
122.
HonguNSachanDS. Caffeine, carnitine and choline supplementation of rats decreases body fat and serum leptin concentration as does exercise. J Nutr. 2000;130:152-157.
123.
WutzkeKDLorenzH. The effect of L-carnitine on fat oxidation, protein turnover, and body composition in slightly overweight subjects. Metabolism. 2004;53:1002-1006.
124.
ElmslieJLPorterRJJoycePRHuntPJMannJI. Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar Disord. 2006;8:503-507.
125.
VillaniRGGannonJSelfMRichPA. L-carnitine supplementation combined with aerobic training does not promote weight loss in moderately obese women. Int J Sport Nutr Exerc Metab. 2000;10:199-207.
126.
CenterSAHarteJWatrousD. The clinical and metabolic effects of rapid weight loss in obese pet cats and the influence of supplemental oral L-carnitine. J Vet Intern Med. 2000;14:598-608.
127.
RubinMRVolekJSGómezAL. Safety measures of L-carnitine L-tartrate supplementation in healthy men. J Strength Cond Res. 2001;15:486-490.
128.
AbourashedEAEl-AlfyATKhanIAWalkerL. Ephedra in perspective: a current review. Phytother Res. 2003;17:703-712.
129.
ChenWLTsaiTHYangCCKuoTB. Effects of ephedra on autonomic nervous modulation in healthy young adults. J Ethnopharmacol. 2010;130:563-568.
130.
AndrawsRChawlaPBrownDL. Cardiovascular effects of ephedra alkaloids: a comprehensive review. Prog Cardiovasc Dis. 2005;47:217-225.
131.
GreenwayFL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev. 2001;2:199-211.
132.
JonderkoKKucioC. Effect of anti-obesity drugs promoting energy expenditure, yohimbine and ephedrine, on gastric emptying in obese patients. Aliment Pharmacol Ther. 1991;5:413-418.
133.
DullooAGMillerDS. Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity. Am J Clin Nutr. 1987;45:564-569.
134.
BreumLPedersenJKAhlstrømFFrimodt-MøllerJ. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity: a double-blind multi-centre trial in general practice. Int J Obes Relat Metab Disord. 1994;18:99-103.
135.
CoffeyCSSteinerDBakerBAAllisonDB. A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. Int J Obes Relat Metab Disord. 2004;28:1411-1419.
136.
BoozerCNDalyPAHomelP. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord. 2002;26:593-604.
137.
GreenwayFL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev. 2001;2:199-211.
138.
ShekellePGHardyMLMortonSC. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289:1537-1545.
139.
SeamonMJClausonKA. Ephedra: yesterday, DSHEA, and tomorrow: a ten year perspective on the Dietary Supplement Health and Education Act of 1994. J Herb Pharmacother. 2005;5:67-86.
140.
CastotALarreyD. Hepatitis observed during a treatment with a drug or tea containing wild germander: evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance [in French]. Gastroenterol Clin Biol. 1992;16:916-922.
141.
LarreyDVialTPauwelsACastotABiourMDavidMMichelH. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med. 1992;117:129-132.
142.
LoeperJDescatoireVLetteronP. Hepatotoxicity of germander in mice. Gastroenterology. 1994;106:464-447.
143.
LekehalMPessayreDLereauJMMoulisCFourasteIFauD. Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology. 1996;24:212-218.
144.
LuoXJPengJLiYJ. Recent advances in the study on capsaicinoids and capsinoids. Eur J Pharmacol. 2011;650:1-7.
145.
SnitkerSFujishimaYShenH. Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications. Am J Clin Nutr. 2009;89:45-50.
146.
JosseARSherriffsSSHolwerdaAMAndrewsRStaplesAWPhillipsSM. Effects of capsinoid ingestion on energy expenditure and lipid oxidation at rest and during exercise. Nutr Metab (Lond). 2010;7:65.
147.
Westerterp-PlantengaMSSmeetsALejeuneMP. Sensory and gastrointestinal satiety effects of capsaicin on food intake. Int J Obes. 2005;29:682-688.
148.
LudyMJMattesRD. The effects of hedonically acceptable red pepper doses on thermogenesis and appetite. Physiol Behav. 2011;102:251-258.
149.
BelzaAFrandsenEKondrupJ. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects. Int J Obes (Lond). 2007;31:121-130.
150.
JooJIKimDHChoiJWYunJW. Proteomic analysis for antiobesity potential of capsaicin on white adipose tissue in rats fed with a high fat diet. J Proteome Res. 2010;9:2977-2987.
151.
LeeRABalickMJ. Indigenous use of Hoodia gordonii and appetite suppression. Explore (NY). 2007;3:404-406.
152.
MacLeanDBLuoLG. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside. Brain Res. 2004;1020:1-11.
153.
HabeckM. A succulent cure to end obesity. Drug Discov Today. 2002;7:280-281.
154.
Oliver-BeverB. Medicinal plants in tropical West Africa, III: anti-infection therapy with higher plants. J Ethnopharmacol. 1983;9:1-83.
155.
Oliver-BeverB. Medicinal plants in tropical West Africa, II: plants acting on the nervous system. J Ethnopharmacol. 1983;7:1-93.
156.
Oliver-BeverB. Medicinal plants in tropical West Africa, I: plants acting on the cardiovascular system. J Ethnopharmacol. 1982;5:1-72.
157.
ObenJENgondiJLMomoCNAgborGASobguiCS. The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids Health Dis. 2008;7:12.
158.
ObenJKuateDAgborGMomoCTallaX. The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Lipids Health Dis. 2006;5:24.
159.
ObenJEEnyegueDMFomekongGISoukontouaYBAgborGA. The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress. Lipids Health Dis. 2007;6:4.
160.
HaazSFontaineKRCutterGLimdiNPerumean-ChaneySAllisonDB. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Rev. 2006;7:79-88.
161.
GreenwayFde Jonge-LevitanLMartinCRobertsAGrundyIParkerC. Dietary herbal supplements with phenylephrine for weight loss. J Med Food. 2006;9:572-578.
162.
PreussHGDiFerdinandoDBagchiMBagchiD. Citrus aurantium as a thermogenic, weight-reduction replacement for ephedra: an overview. J Med. 2002;33:247-264.
163.
ColkerCMKalmanDSTorinaGCPerlisTStreetC. Effects of citrus aurantium extract, caffeine, and St. John’s wort on body fat loss, lipid levels, and mood states in overweight healthy adults. Curr Ther Res. 1999;60:145-153.
164.
AsnaashariSDelazarAHabibiB. Essential oil from Citrus aurantifolia prevents ketotifen-induced weight-gain in mice. Phytother Res. 2010;24:1893-1897.
165.
Dangerous supplements: what you don’t know about these 12 ingredients could hurt you. Consum Rep. 2010;75:16-20.
166.
MadarZStarkAH. New legume sources as therapeutic agents. Br J Nutr. 2002;88:S287-S292.
167.
HannanJMAliLRokeyaB. Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. Br J Nutr. 2007;97:514-521.
168.
XueWLLiXSZhangJLiuYHWangZLZhangRJ. Effect of Trigonella foenum-graecum (fenugreek) extract on blood glucose, blood lipid and hemorheological properties in streptozotocin-induced diabetic rats. Asia Pac J Clin Nutr. 2007;16:422-426.
169.
AnnidaBStanely Mainzen PrinceP. Supplementation of fenugreek leaves reduces oxidative stress in streptozotocin-induced diabetic rats. J Med Food. 2005;8:382-385.
170.
DixitPGhaskadbiSMohanHDevasagayamTP. Antioxidant properties of germinated fenugreek seeds. Phytother Res. 2005;19:977-983.
171.
DakamWShangJAgborGObenJ. Effects of sodium bicarbonate and albumin on the in vitro water-holding capacity and some physiological properties of Trigonella foenum graecum L. galactomannan in rats. J Med Food. 2007;10(1):169-174.
172.
Bin-HafeezBHaqueRParvezSPandeySSayeedIRaisuddinS. Immunomodulatory effects of fenugreek (Trigonella foenum graecum L.) extract in mice. Int Immunopharmacol. 2003;3:257-265.
173.
SharmaRDRaghuramTCRaoNS. Effect of fenugreek seeds on blood glucose and serum lipids in type I diabetes. Eur J Clin Nutr. 1990;44:301-306.
174.
GuptaAGuptaRLalB. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J Assoc Physicians India. 2001;49:1057-1061.
175.
KassaianNAzadbakhtLForghaniBAminiM. Effect of fenugreek seeds on blood glucose and lipid profiles in type 2 diabetic patients. Int J Vitam Nutr Res. 2009;79:34-39.
176.
ChevassusHGaillardJBFarretA. A fenugreek seed extract selectively reduces spontaneous fat intake in overweight subjects. Eur J Clin Pharmacol. 2010;66:449-455.
177.
ChevassusHMolinierNCostaFGaltierFRenardEPetitP. A fenugreek seed extract selectively reduces spontaneous fat consumption in healthy volunteers. Eur J Clin Pharmacol. 2009;65:1175-1178.
178.
BarrettMLUdaniJK. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control. Nutr J. 2011;10:24.
179.
UdaniJSinghBB. Blocking carbohydrate absorption and weight loss: a clinical trial using a proprietary fractionated white bean extract. Altern Ther Health Med. 2007;13:32-37.
180.
UdaniJHardyMMadsenDC. Blocking carbohydrate absorption and weight loss: a clinical trial using phase 2 brand proprietary fractionated white bean extract. Altern Med Rev. 2004;9:63-69.
181.
CellenoLTolainiMVD’AmoreAPerriconeNVPreussHG. A dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. Int J Med Sci. 2007;4:45-52.
182.
MollahMLKimGSMoonHK. Antiobesity effects of wild ginseng (Panax ginseng C.A. Meyer) mediated by PPAR-gamma, GLUT4 and LPL in ob/ob mice. Phytother Res. 2009;23:220-225.
183.
KimHYKangKSYamabeNNagaiRYokozawaT. Protective effect of heat-processed American ginseng against diabetic renal damage in rats. J Agric Food Chem. 20077;55(21):8491-8497.
184.
LianXYZhangZStringerJL. Protective effects of ginseng components in a rodent model of neurodegeneration. Ann Neurol. 2005;57:642-648.
185.
XieJTZhouYPDeyL. Ginseng berry reduces blood glucose and body weight in db/db mice. Phytomedicine. 2002;9:254-258.
186.
LimSYoonJWChoiSH. Effect of ginsam, a vinegar extract from Panax ginseng, on body weight and glucose homeostasis in an obese insulin-resistant rat model. Metabolism. 2009;58:8-15.
187.
KimJHKangSAHanSMShimI. Comparison of the antiobesity effects of the protopanaxadiol- and protopanaxatriol-type saponins of red ginseng. Phytother Res. 2009;23:78-85.
188.
HanLKZhengYNYoshikawaMOkudaHKimuraY. Anti-obesity effects of chikusetsusaponins isolated from Panax japonicus rhizomes. BMC Complement Altern Med. 2005;5:9.
189.
SotaniemiEAHaapakoskiERautioA. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care. 1995;18:1373-1375.
